<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04014205</url>
  </required_header>
  <id_info>
    <org_study_id>ICP-CL-00107</org_study_id>
    <nct_id>NCT04014205</nct_id>
  </id_info>
  <brief_title>A Study of Tyrosine Kinase Inhibitor Orelabrutinib (ICP-022) in Patients With r/r B-Cell Malignancies</brief_title>
  <official_title>A Phase I/II，Multicenter, Open-Label, Study of a Novel Bruton's Tyrosine Kinase Inhibitor, Orelabrutinib, in Patients With B-Cell Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing InnoCare Pharma Tech Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing InnoCare Pharma Tech Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase I/II, multicenter, open-label study to evaluate the safety, efficacy,&#xD;
      tolerability, and pharmacokinetics of a novel BTK inhibitor, Orelabrutinib (ICP-022) in&#xD;
      Patients with B-cell malignancies. The study contains two parts, Part 1 (dose escalation) and&#xD;
      Part 2 (dose expansion).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 18, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1 Dose Escalation：The maximum tolerated dose (MTD)</measure>
    <time_frame>Incidence of dose limiting toxicities (DLTs) up to 28 days</time_frame>
    <description>To determine the maximum tolerated dose (MTD)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2 Dose Expansion：ORR</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>To assess anti-tumor activity of Orelabrutinib (ICP-022) in Patients with B-cell malignancies including r/r MCL, r/r FL, r/r MZL and CLL/SLL with/without prior treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part 1 Dose Escalation：Incidence and severity of treatment-emergent adverse events (AEs) [Safety and Tolerability]</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>The incidence and severity of treatment-emergent AEs will be collected and the safety and tolerability of ICP-022 will be assessed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1 Dose Escalation：ORR</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Objective response rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1 Dose Escalation：T1/2</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Elimination half-life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2 Dose Expansion：Incidence and severity of treatment-emergent adverse events (AEs) [Safety and Tolerability]</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>The incidence and severity of treatment-emergent AEs will be collected and the safety and tolerability of ICP-022 will be assessed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2 Dose Expansion：DOR</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Duration of response</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">81</enrollment>
  <condition>Part 1：r/r B-cell Malignancies</condition>
  <condition>Part 2：B-cell Malignancies</condition>
  <arm_group>
    <arm_group_label>Part 1 Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with r/r B-cell malignancies including Grades 1-3a FL, MZL, MCL, and CLL/SLL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 Dose Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm 1: Patients with r/r MCL&#xD;
Arm 2: Patients with other types of B-cell malignancies, including:&#xD;
CLL/SLL with/without prior treatment&#xD;
r/r FL&#xD;
r/r MZL</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Orelabrutinib (ICP-022)</intervention_name>
    <description>ICP-022 The drug product is a white, round, uncoated tablet</description>
    <arm_group_label>Part 1 Dose Escalation</arm_group_label>
    <arm_group_label>Part 2 Dose Expansion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed Informed Consent.&#xD;
&#xD;
          2. Age ≥ 18 years.&#xD;
&#xD;
          3. Part 1: Patients with histologically confirmed relapsed or refractory B-cell&#xD;
             malignancies, including Grades 1-3a FL, MZL, MCL, and CLL/SLL.&#xD;
&#xD;
             Part 2: Patients with histologically confirmed B-cell malignancies including r/r FL,&#xD;
             r/r MZL and CLL/SLL with/without prior treatment.&#xD;
&#xD;
          4. Life expectancy (in the opinion of the investigator) of ≥ 4 months.&#xD;
&#xD;
          5. ECOG performance status of 0 ~1.&#xD;
&#xD;
          6. Must have adequate organ function.&#xD;
&#xD;
          7. Negative test results for HBV ([HBsAg (-)] and non-active HBV or HCV infection&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant or breast-feeding or intending to become pregnant during the study.&#xD;
&#xD;
          2. Prior treatment with systemic immunotherapeutic agents.&#xD;
&#xD;
          3. Known allergies to Orelabrutinib (ICP-022) or its excipients or infection with HIV.&#xD;
&#xD;
          4. Treatment with any chemotherapeutic agent, or any other investigational therapies&#xD;
             within 4 weeks prior to first dose of the study drug.&#xD;
&#xD;
          5. History of allogeneic stem-cell (or other organ) transplantation or confirmed&#xD;
             progressive PML.&#xD;
&#xD;
          6. Any external beam radiation therapy within 6 weeks prior to the first dose of the&#xD;
             study drug.&#xD;
&#xD;
          7. Concurrent use of warfarin or other vitamin K antagonists or anticoagulation therapies&#xD;
             or strong CYP3A inhibitor.&#xD;
&#xD;
          8. Active uncontrolled infections.&#xD;
&#xD;
          9. Recent infection requiring IV anti-infective treatment that was completed ≤ 14 days&#xD;
             before the first dose of study drug.&#xD;
&#xD;
         10. Unresolved toxicities from prior anti-cancer therapy.&#xD;
&#xD;
         11. Medically apparent CNS lymphoma or leptomeningeal disease.&#xD;
&#xD;
         12. Current or previous history of CNS disease.&#xD;
&#xD;
         13. Major surgery or significant traumatic injury &lt; 28 days prior to the first dose of the&#xD;
             study drug.&#xD;
&#xD;
         14. Patients with another invasive malignancy in the last 2 years.&#xD;
&#xD;
         15. Significant cardiovascular disease or active pulmonary disease.&#xD;
&#xD;
         16. Received systemic immunosuppressive medications.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Olivia Yang</last_name>
    <phone>+1 (609) 524-0684</phone>
    <email>ClinicalTrialsInfo@innocarepharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Desert Hematology Oncology Medical Group, Inc.</name>
      <address>
        <city>Rancho Mirage</city>
        <state>California</state>
        <zip>92270</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luke Dreisbach</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Asclepes Research Centers - Weeki Wachee</name>
      <address>
        <city>Weeki Wachee</city>
        <state>Florida</state>
        <zip>34607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Kerr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northwest Neurology - Rolling Meadows Office</name>
      <address>
        <city>Elk Grove Village</city>
        <state>Illinois</state>
        <zip>60007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruce Bank</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Orchard Healthcare Research Inc.</name>
      <address>
        <city>Skokie</city>
        <state>Illinois</state>
        <zip>60077</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ira Oliff</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cotton O'Neil Cancer Center (Stormont-Vail Cancer Center)</name>
      <address>
        <city>Topeka</city>
        <state>Kansas</state>
        <zip>66606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Einspahr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tulane University School of Medicine - Tulane Cancer Center Comprehensive Clinic TCCCC</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Saba Nakhle</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic - Minnesota</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905-0001</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yucai Wang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Coborn Cancer Center</name>
      <address>
        <city>Saint Cloud</city>
        <state>Minnesota</state>
        <zip>56303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donald Jurgens</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St Vincent Frontier Cancer Center</name>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <zip>59102-6746</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cobb W Patrick</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Southeast Nebraska Cancer Center</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68510-2496</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steve Dunder, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Summit Medical Group</name>
      <address>
        <city>Florham Park</city>
        <state>New Jersey</state>
        <zip>07932-0001</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gallinson H David</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Research Alliance</name>
      <address>
        <city>Westbury</city>
        <state>New York</state>
        <zip>11590</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Coleman Morton</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gabrail Cancer Research Center</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nashat Gabrail</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tennessee Cancer Specialists</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37909-1327</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Lee, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael (Luhua) Wang</last_name>
    </contact>
    <contact_backup>
      <phone>713-792-2860</phone>
      <email>miwang@mdanderson.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Medical Oncology Associates PS (dba Summit Cancer Centers)</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chaudhry Arvind</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 18, 2019</study_first_submitted>
  <study_first_submitted_qc>July 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 10, 2019</study_first_posted>
  <last_update_submitted>October 20, 2021</last_update_submitted>
  <last_update_submitted_qc>October 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

